contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


immunovia-ab-immunovia-presents-data-from-discovery-study-at-2024-pancreasfest-medical-conference

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Immunovia is a biotechnology company. The company's research and development is focused on molecular diagnostics, where the business focuses on driving the development and change of current working methods for diagnosing complex cancers and immune diseases. The vision is to establish blood-based tests to be able to identify different types of pancreatic cancer at an early stage. The company was founded in 2007 and is headquartered in Lund.

Immunovia

LUND (SWEDEN) - Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today presented detailed discovery study results for the company's next-generation early detection...

<div class="abstract">LUND (SWEDEN) - Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today presented detailed discovery study results for the company's next-generation early detection test for pancreatic cancer at the PancreasFest 2024 Annual Meeting (abstract #P33).&nbsp;</div>PancreasFest is an annual conference of physicians and translational researchers with special interest in the pancreas who convene to find new ways to improve the care of patients with pancreatic disease, including pancreatic cancer. It is organized by the Collaborative Alliance for Pancreatic Education and Research.&nbsp; Abstracts submitted to this medical conference undergo a rigorous peer-review and selection process in which only a subset of studies are chosen for presentation at the meeting.Results presented at PancreasFest reflect a detailed scientific presentation of the initial positive data the company shared in a 7 November 2023 press release.The discovery study, the most comprehensive pancreatic cancer proteomics study done to date, identified 15 promising protein biomarkers that were shown to strongly correlate with the presence of pancreatic ductal adenocarcinoma (PDAC). These protein biomarkers demonstrated the ability to differentiate PDAC cases from non-PDAC controls. Over 3,000 proteins were evaluated in 329 blood samples from Stage 1 and II PDAC and non-PDAC matched control patients using Olink multiplex technology and conventional immunoassays."We are honored to have been chosen to present the discovery study results at this important conference.&nbsp; We look forward to discussing the detailed study data and receiving scientific and clinical insights from this key group of physicians and researchers who are experts in pancreatic cancer," said Norma Palma PhD, Vice President of Clinical and Medical Affairs at Immunovia.For more information, please contact:Jeff BorcherdingCEO and Presidentjeff.borcherding@immunovia.comKarin Almqvist LiwendahlChief Financial Officerkarin.almqvist.liwendahl@immunovia.com+46 709 11 56 08Immunovia in briefImmunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer.Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.USA is the world's largest market for detection of pancreatic cancer. The company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit &nbsp;(<a href="http://www.immunovia.com/">http://www.immunovia.com/</a>)www.immunovia.com

Immunovia AB: Immunovia presents data from discovery study at 2024 PancreasFest medical conference

Stay up to date with our newsletter